BR112012011777A2 - tratamento da exacerbação aguda de asma e redução da probabilidade de hospitalização de pacientes que sofrem dela. - Google Patents

tratamento da exacerbação aguda de asma e redução da probabilidade de hospitalização de pacientes que sofrem dela.

Info

Publication number
BR112012011777A2
BR112012011777A2 BR112012011777A BR112012011777A BR112012011777A2 BR 112012011777 A2 BR112012011777 A2 BR 112012011777A2 BR 112012011777 A BR112012011777 A BR 112012011777A BR 112012011777 A BR112012011777 A BR 112012011777A BR 112012011777 A2 BR112012011777 A2 BR 112012011777A2
Authority
BR
Brazil
Prior art keywords
acute
hospitalization
treatment
patients suffering
reduced likelihood
Prior art date
Application number
BR112012011777A
Other languages
English (en)
Inventor
Kazuko Matsuda
Kirk W Johnson
Yuichi Iwaki
Original Assignee
Medicinova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicinova Inc filed Critical Medicinova Inc
Publication of BR112012011777A2 publication Critical patent/BR112012011777A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

tratamento da exacerbação aguda de asma e redução da probabilidade de hospitalização de pacientes que sofrem dela. a invenção proporciona um método de melhorar um ou mais resultados clínicos de um indivíduo que experimenta um ataque respiratório agudo. o ataque respiratório agudo podem incluir broncoespasmo reversível aguda, broncoespasmo agudo grave ou exacerbação aguda de asma. o método inclui a administração de uma quantidade eficaz de bedoradrine ou de um sal farmaceuticamente aceitável do mesmo em combinação com um padrão de cuidados do regime de tratamento (soc). um indivíduo que sofre de um ataque respiratório agudo uma.
BR112012011777A 2009-11-18 2010-11-17 tratamento da exacerbação aguda de asma e redução da probabilidade de hospitalização de pacientes que sofrem dela. BR112012011777A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26235209P 2009-11-18 2009-11-18
US39291710P 2010-10-13 2010-10-13
PCT/US2010/057028 WO2011062984A1 (en) 2009-11-18 2010-11-17 Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom

Publications (1)

Publication Number Publication Date
BR112012011777A2 true BR112012011777A2 (pt) 2015-10-13

Family

ID=44011454

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012011777A BR112012011777A2 (pt) 2009-11-18 2010-11-17 tratamento da exacerbação aguda de asma e redução da probabilidade de hospitalização de pacientes que sofrem dela.

Country Status (11)

Country Link
US (3) US20110117213A1 (pt)
EP (1) EP2501228A4 (pt)
JP (1) JP2013511528A (pt)
KR (1) KR20140015150A (pt)
CN (1) CN102365017A (pt)
AU (1) AU2010322066A1 (pt)
BR (1) BR112012011777A2 (pt)
CA (1) CA2781061A1 (pt)
MX (1) MX2012005661A (pt)
TW (1) TW201121540A (pt)
WO (1) WO2011062984A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120295982A1 (en) * 2011-02-22 2012-11-22 Medicinova, Inc. Treating human male copd patients with oral bedoradrine
RU2676333C2 (ru) * 2013-08-12 2018-12-28 Астразенека Аб Способы снижения частоты приступов астмы с применением бенрализумаба

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW375604B (en) * 1996-02-19 1999-12-01 Kissei Pharmaceutical 3,4-di-substituting phenyl-ethanolamine-tetrahydronaphthyl carboxylic amide derivatives
JP3708624B2 (ja) * 1996-03-27 2005-10-19 キッセイ薬品工業株式会社 ３，４−ジ置換フェニルエタノールアミノテトラリンカルボン酸誘導体
US20080081825A1 (en) * 2004-04-28 2008-04-03 Hisao Nakai Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof
EP1819347A1 (en) * 2004-11-30 2007-08-22 Aventis Pharmaceuticals, Inc. Treating acute exacerbations of asthma using a ketolide

Also Published As

Publication number Publication date
AU2010322066A1 (en) 2012-06-21
JP2013511528A (ja) 2013-04-04
CN102365017A (zh) 2012-02-29
US20110117213A1 (en) 2011-05-19
TW201121540A (en) 2011-07-01
EP2501228A4 (en) 2013-11-13
US20140056999A1 (en) 2014-02-27
CA2781061A1 (en) 2011-05-26
KR20140015150A (ko) 2014-02-06
MX2012005661A (es) 2012-09-07
EP2501228A1 (en) 2012-09-26
US8420697B2 (en) 2013-04-16
US20120251632A1 (en) 2012-10-04
WO2011062984A1 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
Khan et al. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder
WO2007103373A3 (en) Compositions and methods for the treatment of immunoinflammatory disorders
UY32177A (es) Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
BRPI0921999B8 (pt) uso de uma quantidade terapeuticamente eficaz de células tronco placentárias
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
BRPI0909894A2 (pt) "método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica.
CO6390109A2 (es) Inhibidores de syk de imidazopirazina
CY1115350T1 (el) Χρησεις αναστολεων της dpp iv
WO2011139345A3 (en) Pathway recognition algorithm using data integration on genomic models (paradigm)
WO2007002927A3 (en) Imaging geometry
BR112014003117A2 (pt) inibidores da corrente funny (if) para uso em um método de tratamento e prevenção de insuficiência cardíaca em felino
WO2012083132A3 (en) Diagnosis and treatments relating to th2 inhibition
MY166890A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
ECSP099556A (es) Nuevos métodos
SG170044A1 (en) Ocular allergy treatments
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
WO2013016315A8 (en) Methods for treating niemann-pick type c disease
AR053928A1 (es) Metodos reactivos para el tratamiento de trastornos inflamatorios
CL2012000586A1 (es) Uso de al menos 20 mg de un aerosol de una solucion que comprende levofloxacina u ofloxacina y un cation bivalente o trivalente, para el tratamiento de una infeccion pulmonar en un paciente con fibrosis quistica.
AR086395A1 (es) Envase para el tratamiento de patologias
WO2009027703A3 (en) Identifying organ damage
BR112012011777A2 (pt) tratamento da exacerbação aguda de asma e redução da probabilidade de hospitalização de pacientes que sofrem dela.
NZ611614A (en) Compositions and methods for treating amyloid plaque associated symptoms
BRPI0819195A2 (pt) métodos para tratar escleroderma em um paciente em necessidade de tal tratamento e para aliviar um ou mais dos sintomas associados com escleroderma em um paciente em necessidade de tal tratamento.
Fakhar et al. Post‐COVID‐19 maxillary osteonecrosis and floating maxillary teeth due to mucormycosis in two uncontrolled diabetic patients

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]